Skip to main content

What Zoetis's Quarter ended Sep 30, 2026 10-Q says: 7 signals

Zoetis filed its latest 10-Q with the SEC on Nov 5, 2026. It discusses bookings decline, international growth and margin pressure.

Public (ZTS)Pharmaceutical Manufacturing10,000+ employeeszoetis.comLinkedIn

Get Zoetis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Zoetis this week? Use Autobound signals for zoetis.com.
Filed
Nov 5, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
18

Source: Autobound Signal API · 80 signals tracked for Zoetis · updated

10-Q · latest 10

What Zoetis's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 7 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 7 signals

    SEC EDGAR

Earlier 10-Q filings

  • 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR

Showing 10 of 18 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Zoetis earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Dermatology share loss slowed to 4 points in quarterThe key dermatology portfolio saw global revenue decline 16% to $396 million, including a 13% decline in the U.S. driven by market share losses in Apoquel against new competitive entrants. Promotional defense investments helped moderate U.S. dermatology share loss to 4 points in Q3 from 7 points in Q2.
Livestock revenue grows 7% to $797M across international marketsLivestock revenue rose 7% globally to $797 million, serving as a bright spot offset to companion animal weakness. International livestock surged 9% to $531 million, led by cattle strength and fish performance in Norway, while U.S. livestock grew 5% to $266 million.
Full-year adjusted net income guidance raised to $2.64BManagement raised full-year adjusted net income guidance to $2.60B-$2.64B and adjusted diluted EPS guidance to $6.25-$6.35. Revenue guidance was narrowed toward the high end at $9.22B-$9.32B.
Jay Saccaro appointed as Chief Financial Officer and COOJay Saccaro attended his first earnings call as Chief Financial Officer and Chief Operating Officer, initiating a comprehensive review of the company's cost structure and operational guidance metrics. Executive transitions at the CFO/COO level frequently trigger reviews of operating expenses, vendor contracts, and enterprise software stacks.
Convenia RTU approved in US and launching in CanadaConvenia RTU for dogs has secured regulatory approval in the U.S. and is set to launch in Canada, offering up to 14 days of treatment via a single injection. The company is actively introducing lifecycle innovations to defend against generic pressure on legacy Convenia and Cerenia.
Increased R&D spending on data and digital initiativesAdjusted R&D spending totaled $174 million in Q3, reflecting targeted investments in data and digital initiatives alongside pipeline project progression. These tech investments were offset by corporate cost and productivity savings in professional services and incentive compensation.

Signal API · MCP

Track Zoetis with the Signal API

One POST /v1/companies/enrich call with zoetis.com returns Zoetis 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"zoetis.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Zoetis 10-Q

When did Zoetis file its latest 10-Q?
Zoetis filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 5, 2026. The one before it was filed on Aug 6, 2026.
What did Zoetis disclose in its latest 10-Q?
From the filing dated Nov 5, 2026: Zoetis begins rollout of multi-year enterprise resource planning (ERP) system to replace core systems
What did Zoetis say on its recent earnings calls?
Q3 FY2026: Dermatology share loss slowed to 4 points in quarter (dated Nov 5, 2026).
Where can I read Zoetis's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1555280/000155528026000050/zts-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →